Physician profile
Amy E Bailey
NPI 1003161373
$1,731.52
in general payments reported to CMS, 2019-2025
22 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.89 · 2022: $165 · 2023: $652 · 2024: $434 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $394.53 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $237.47 | 2022-2025 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $221.49 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $132.72 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $101.03 | 2023-2024 | |
| Shield Therapeutics INC | $100.77 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.64 | 2022-2023 | Jardiance |
| Astellas Pharma US INC | $57.61 | 2023-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $57.19 | 2023-2024 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $46.38 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $45.32 | 2023-2025 | |
| Amgen INC. | $38.83 | 2024-2025 | Otezla, Repatha, Repatha |
| Genentech USA, INC. | $36.89 | 2021 | |
| Merck Sharp & Dohme LLC | $35.79 | 2024 | Capvaxive |
| Pfizer INC. | $25.04 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.75 | 2025 | Watchman Flx |
| Corcept Therapeutics | $21.74 | 2023 | Korlym |
| Exeltis, USA INC. | $20.80 | 2024 | Slynd |
| Scynexis, INC. | $16.91 | 2022 | |
| Seqirus USA INC | $15.29 | 2024 | Flucelvax, Fluad |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2022 | |
| Phathom Pharmaceuticals, INC. | $9.48 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.